E-LIB Suche - Ergebnisse für: Herbaux, C.

1

Tafasitamab lenalidomide in relapsed/refractory large B‐cel..:

Paillassa, J. ; Degoutte, C. ; Oberic, L....
Hematological Oncology. 41 (2023) S2 - p. 591-592 , 2023

Link: https://doi.org/10.1002/..

2

Long term follow‐up of untreated/relapsing MCL patients wit..:

Le Gouill, S. ; Morschhauser, F. ; Chiron, D....
Hematological Oncology. 41 (2023) S2 - p. 478-479 , 2023

Link: https://doi.org/10.1002/..

3

Tandem versus single haematopoietic stem cell transplant an..:

Marouf, A. ; Molinari, N. ; Sibon, D....
British Journal of Haematology. 202 (2023) 2 - p. 379-383 , 2023

Link: https://doi.org/10.1111/..

4

Pola‐R‐CHP versus R‐CHOEP in young patients with high‐risk ..:

Lenz, G. ; Tilly, H. ; Ziepert, M....
Hematological Oncology. 41 (2023) S2 - p. 420-421 , 2023

Link: https://doi.org/10.1002/..

5

Subgroup analysis of elderly patients (pts) with diffuse la..:

Hu, B. ; Reagan, P. M. ; Sehn, L. H....
Hematological Oncology. 41 (2023) S2 - p. 416-418 , 2023

Link: https://doi.org/10.1002/..

6

Cause of death and prognosis of patients (pts) with primary..:

Herbaux, C. ; Dietrich, S. ; McMillan, A....
Hematological Oncology. 41 (2023) S2 - p. 432-433 , 2023

Link: https://doi.org/10.1002/..

7

KILT: A RANDOMIZED NON‐COMPARATIVE PHASE II LYSA STUDY OF L..:

Cheminant, M. ; Carras, S. ; Bruneau, J....
Hematological Oncology. 41 (2023) S2 - p. 838-839 , 2023

Link: https://doi.org/10.1002/..

8

P1133: SUB-CUTANEOUS RITUXIMAB INDUCTION FOLLOWED BY SHORT ..:

Cartron, G. ; Bachy, E. ; Tilly, H....
HemaSphere. 6 (2022) - p. 1023-1024 , 2022

Link: https://doi.org/10.1097/..

9

P844: CHARACTERIZATION OF MULTIPLE MYELOMA CELL LINES WITH ..:

De Boussac, H. ; Machura, A. ; Steer, A....
HemaSphere. 6 (2022) - p. 738-739 , 2022

Link: https://doi.org/10.1097/..

10

P1190: OUTCOMES BY BCL2 AND MYC EXPRESSION AND REARRANGEMEN..:

Morschhauser, F. ; Jiang, Y. ; Jardin, F....
HemaSphere. 6 (2022) - p. 1076-1077 , 2022

Link: https://doi.org/10.1097/..

11

PROSPECTIVE EVALUATION OF LYMPHOMA RESPONSE TO IMMUNOMODULA..:

Al Tabaa, Y. ; Casasnovas, O. ; Baillet, C....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

12

A WIDE T‐CELL EXHAUSTION PATTERN IS FREQUENTIN THE TUMOR MI..:

Laurent, C ; Syrykh, C ; Herbaux, C...
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

13

ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH R..:

Herbaux, C. ; Schiano de Colella, J. M. ; Thieblemont, C....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

14

Correction to: Risk of relapse after anti-PD1 discontinuati..:

Manson, G. ; Brice, P. ; Herbaux, C....
European Journal of Nuclear Medicine and Molecular Imaging. 48 (2021) 5 - p. 1699-1700 , 2021

Link: https://doi.org/10.1007/..

15

ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH R..:

Cartron, G. ; Bachy, E. ; Guidez, S....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..